Catalyst Dossier · compiled by CeliA 🧫

Crinetics Pharmaceuticals, Inc. (CRNX)

Pharmaceutical Preparations · market cap $3.8B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Crinetics Pharmaceuticals (CRNX) is a San Diego-based specialty pharma company focused on endocrine diseases, with paltusotine (Phase 3, acromegaly) as its lead asset and atumelnant advancing into Phase 3 for congenital adrenal hyperplasia. The company is pre-revenue in any meaningful sense ($8M in 2025), burning approximately $465M net annually, and carries a reported cash runway of only ~2.8 months against a $3.87B market cap — a financing situation that demands immediate scrutiny.

The catalyst path

2026-08-04Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Paltusotine	Phase 3	Acromegaly
atumelnant (CRN04894)	Phase 2	Congenital Adrenal Hyperplasia
Randomized: 40 mg Paltusotine	Phase 2	Carcinoid Syndrome
Atumelnant	Phase 3	Congenital Adrenal Hyperplasia
CRN09682	Phase 2	SST2-positive Neuroendocrine Neoplasms

Price & technical context

3-month

+6.5%

6-month

-18.6%

12-month

+36.1%

52-wk range

$26.85–$56.43

vs 50-day MA

+5.3%

vs 200-day MA

-7.5%

Realized vol

57.3%

Max drawdown

-57.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CRNX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.